Pre-clinical results showed that A2-CAR CD8+ Tregs were significantly more effective than polyclonal CD8+ Tregs in preventing human skin transplant and xeno-GvHD in mice (46) (Figure 1). This evidence concerns the gene CD8A and graft versus host disease.